Cargando…
Development of a variant of dinutuximab with enhanced antitumor efficacy and reduced induction of neuropathic pain
Dinutuximab (ch14.18) was the first approved monoclonal antibody against the tumor‐associated antigen disialoganglioside GD2. Despite its success in treating neuroblastoma (NB), it triggers a significant amount of neuropathic pain in patients, possibly through complement‐dependent cytotoxicity (CDC)...
Autores principales: | Liu, Xin‐Yuan, Chen, Yi‐Li, Liu, Guo‐Jian, Deng, Xiang‐Nan, Cui, Yue, Tan, Jie, Dong, Xing‐Chen, Li, Hua‐Ying, Chen, Gan‐Jun, Ou, Zhi‐Min, Wang, Chun‐He |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9433816/ https://www.ncbi.nlm.nih.gov/pubmed/35792784 http://dx.doi.org/10.1002/2211-5463.13464 |
Ejemplares similares
-
Mechanisms, Characteristics, and Treatment of Neuropathic Pain and Peripheral Neuropathy Associated with Dinutuximab in Neuroblastoma Patients
por: Mastrangelo, Stefano, et al.
Publicado: (2021) -
Dinutuximab beta for neuroblastoma
Publicado: (2020) -
Treatment of High-Risk Neuroblastoma with Dinutuximab and Chemotherapy Administered in all Cycles of Induction
por: Cupit-Link, Margaret, et al.
Publicado: (2023) -
Nivolumab and dinutuximab beta in two patients with refractory
neuroblastoma
por: Ehlert, Karoline, et al.
Publicado: (2020) -
Early Use of Dinutuximab Beta in Patients with High-Risk Neuroblastoma
por: Spasov, Neofit, et al.
Publicado: (2021)